Continuing Medical Education Information: Designs for Early-Phase Clinical Trials

General Accreditation Information

The American Society of Clinical Oncology (ASCO) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This live activity has been approved for a maximum of 8 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

All nonphysician attendees are welcome to submit a request for a Certificate of Participation, through the submission of the evaluation form, which may enable nonphysicians to apply their Annual Meeting participation toward re-licensure. Specific nursing and pharmacy continuing education credit is no longer offered.

Any questions related to CME may be directed to ASCO Staff at cme@asco.org or 571-483-1403.

Needs Statement

The challenges of the next generation of clinical trials will require innovative designs. For the first time, ASCO and the Society for Clinical Trials (SCT) are collaborating to offer education on clinical trial design. This educational forum is focused on developing and applying innovative designs to answer the scientific questions posed in early phase clinical trials in oncology and to improve the efficiency of drug discovery and development. In efforts to bridge the gap between bench to bedside, the education is focused on effective design, development of effective treatments to provide better treatment for cancer patients.    

Design smarter, faster clinical trials to provide evidence for effective treatments targeted to patients most likely to benefit, sooner.

Target Audience

Cosponsored by the Society for Clinical Trials, this seminar is designed for physicians, researchers and fellows interested in clinical trial design and implementation. The seminar may also be of benefit to nurses, pharmacists,   physician assistants, and other health care professionals involved in cancer clinical research.

Learning Objectives

Upon participation in this activity, attendees will be able to:

• Select appropriate endpoints and designs for phase I and II settings
• Compare and contrast designs, methodologies, and implementation of early phase clinical trials
• Effectively address issues that may arise in using enrichment, adaptive or multistage designs in an early phase clinical trial.
• Evaluate medical literature for phase I and phase II clinical trials
  

This activity was planned in the context of the following ACGME competencies:  Medical Knowledge, Professionalism, and Systems-based Practice.

Unlabelled Usage Statement

The information presented is that of the contributing faculty and does not necessarily represent the views of the American Society of Clinical Oncology and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information including indications, contraindications, warnings, precautions and adverse effects.